Jenkins, V.A., Low, R. and Mitra, S. (2009) Hearing sensitivity in women following chemotherapy treatment for breast cancer: Results from a pilot study. Breast, 18 (5). pp. 279-283. ISSN 0960-9776Full text not available from this repository.
PURPOSE: Our aim was to examine in a prospective pilot study whether standard adjuvant treatments for breast cancer can adversely affect hearing. METHODS: Eight pre/peri-menopausal women with breast cancer had middle ear analysis (tympanometry) and pure tone audiometry conducted prior to and 6 months following Fluorouracil, Epirubicin, Cyclophosphamide (FEC) or FEC plus taxotere chemotherapy treatments. RESULTS: The mean hearing thresholds in both ears showed an elevation (that is a decline) post chemotherapy treatment at 6 and 8kHz of between 20 and 30dB, which is graded as a mild hearing impairment at the higher frequency range. There were individual differences in pattern and grade within the group. CONCLUSIONS: The variability noted in the data is more than that would be anticipated for test-retest variance, suggesting that the hearing impairments are complex but genuine. The most likely cause of the reduction in hearing sensitivity is a change in oestrogen levels resulting from the breast cancer treatments.
|Additional Information:||Journal article IDS Number: 526FZ|
|Keywords:||hearing chemotherapy breast cancer|
|Schools and Departments:||Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)|
|Subjects:||R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RG Gynecology and obstetrics > RG0491 Diseases of the breast
R Medicine > RM Therapeutics. Pharmacology > RM0260 Chemotherapy
|Depositing User:||Tracy Woodcock|
|Date Deposited:||26 Aug 2011 14:29|
|Last Modified:||26 Jun 2012 13:32|
|Google Scholar:||1 Citations|